Retractable Technologies Reports Q3 2025 Net Income of $371,047, Revenue Decline

Retractable Technologies, Inc. reported its financial results for the third quarter and the first nine months of 2025, revealing a net income of $371,047 for the three months ending September 30, 2025, compared to a net loss of $1,921,989 for the same period in 2024. For the nine-month period, the company recorded a net loss of $10,217,140, an improvement from a loss of $15,657,246 in the prior year. Revenue for the third quarter was $10,085,723, a slight decrease from $10,346,857 in the same quarter of 2024, while year-to-date revenue increased to $28,826,629 from $23,975,584, marking an increase of 20.4%.

The company experienced a notable shift in its sales mix, with syringes accounting for 65% of total sales in the first nine months of 2025, while EasyPoint® products made up 31.3%. International sales saw a significant increase of 38.1% year-over-year, although the average selling price per unit declined due to a shift in product mix. The company also reported a decrease in the cost of manufactured products by 20.1% in the third quarter, attributed to lower unit sales and a favorable shift in product mix, which contributed to improved gross margins.

Operationally, Retractable Technologies has been adapting its manufacturing capabilities to reduce reliance on imports from China, which accounted for 61.7% of its products in the first nine months of 2025, down from 90% in the same period of 2024. The company is investing in domestic production, including the adaptation of equipment to produce 0.5 mL syringes, with expectations for commercial quantities to be available in the first half of 2026. However, the ongoing tariffs on imported goods, which have increased to 130% for syringes and needles, are expected to continue impacting the company's costs and financial performance.

The company’s balance sheet as of September 30, 2025, showed total assets of $146,434,200, a decrease from $160,724,202 at the end of 2024. Current liabilities increased to $9,627,646 from $8,780,916, while stockholders' equity fell to $76,780,718 from $87,170,691. The company reported cash and cash equivalents of $3,444,538, down from $4,235,388 at the end of 2024. The management indicated that they expect to meet short-term operational needs through cash reserves and revenues, despite the anticipated decline in liquidity due to increased manufacturing costs and tariffs.

Looking ahead, Retractable Technologies aims to enhance its domestic manufacturing capabilities while managing the financial impact of tariffs. The company is focused on increasing production efficiency and reducing reliance on imports, which may lead to higher costs in the short term but is expected to stabilize operations in the long run. The management remains cautious about future market conditions, particularly regarding public sentiment towards vaccinations and the potential for government orders, which have been significant in the past.